Skip to main content
. 2020 Mar 5;12(3):234. doi: 10.3390/pharmaceutics12030234

Table 5.

Actual experiments conducted and responses observed using the hybrid Design of Experiments (DOE).

Run HPMC-AS (g) Eudragit®L100 (g) Homogenisation Speed (rpm) Yield (%) INH Released at 4 h (%) INH Released at 12 h (%) Encapsulation Efficiency (%) INH Released at 24 h (%)
1 3.41 2.00 1500 51.32 17.45 45.35 89.67 80.26
2 2.00 2.00 2000 43.30 29.74 64.44 72.57 89.56
3 2.00 2.00 500 56.52 23.30 55.35 77.42 87.45
4 3.00 3.00 2500 48.32 19.05 36.25 65.16 71.28
5 0.485 2.00 1500 21.91 38.42 65.41 50.51 93.16
6 3.00 1.00 2500 45.83 39.33 53.99 70.99 88.67
7 1.00 3.00 2500 40.00 13.02 59.45 68.65 95.20
8 2.00 0.485 1500 21.14 71.04 55.78 55.48 89.81
9 2.00 2.00 3500 31.83 36.66 68.89 60.84 93.58
10 1.00 1.00 2500 22.27 45.86 67.51 66.72 90.96
11 2.00 3.41 1500 47.17 8.82 47.75 89.41 87.87